Overview
- Editors:
-
-
Angus G. Dalgleish
-
Division of Oncology, St. George’s Hospital Medical School, London, UK
-
Burkhard Haefner
-
Department of Oncology Johnson and Johnson Pharmaceutical, Research and Development, Beerse, Belgium
- The focus is on NF-kB as a crucial regulator of inflammatory response, driver of tumorigenesis in many types of cancer and key drug target
- Provides cross-disciplinary approach (cancer/inflammation research) promoting a more holistic understanding (thinking outside of the box) of the complex process of tumorigenesis
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (10 chapters)
-
-
- Angus G. Dalgleish, Ken O’Byrne
Pages 1-38
-
- Lindsey Jackson, B. Mark Evers
Pages 39-65
-
- Arndt J. Schottelius, Harald Dinter
Pages 67-87
-
- Linda Vermeulen, Wim Vanden Berghe, Guy Haegeman
Pages 89-102
-
-
-
-
- Jessica Bertout, Andrei Thomas-Tikhonenko
Pages 167-197
-
- Josep M. Argilés, Sílvia Busquets, Francisco J. López-Soriano
Pages 199-217
-
-
Back Matter
Pages 247-254
About this book
A link between inflammation and cancer has been established many years ago, yet it is only recently that the potential significance of this connection has become apparent. Although several examples of chronic inflammatory conditions, often induced by persistent irritation and/or infection, developing into cancer have been known for some time, there has been a notable resistance to contemplate the possibility that this association may apply in a causative way to other cancers. Examples for such progression from chronic inflammation to cancer are colon carcinoma developing with increased frequency in patients with ulcerative colitis, and the increased incidence of bladder cancer in patients suffering from chronic Schistosoma infection. Inflammation and cancer have been recognized to be linked in another context for many years, i.e., with regards to pathologies resembling chronic lacerations or 'wounds that do not heal.' More recently, the immunology of wound healing has given us clues as to the mechanistic link between inflammation and cancer, in as much as wounds and chronic inflammation turn off local cell-mediated immune responses and switch on growth factor release as well the growth of new blood vessels - angiogenesis. Both of these are features of most types of tumours, which suggest that tumours may require an immunologically shielded milieu and a growth factor-rich environment.
Editors and Affiliations
-
Division of Oncology, St. George’s Hospital Medical School, London, UK
Angus G. Dalgleish
-
Department of Oncology Johnson and Johnson Pharmaceutical, Research and Development, Beerse, Belgium
Burkhard Haefner